Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab efficacy predictors in refractory lupus nephritis
ChiCTR2600134758Phase 4Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of belimumab in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: 6-month complete renal remission. Started Jan 2026; status: recruiting.
02
Drugs
belimumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2600134758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134758.